** Shares of Cann Group Ltd CAN.AX rise as much as 5.4% to
A$0.295, their highest since Feb 2
** The medical cannabis manufacturer says it has entered o
an evaluation-and-option agreement with GSK Consumer
Healthcare urn:newsml:reuters.com:*:nFWN2W30UF
** Says agreement is for potential commercialisation of co's
Satipharm CBD capsules for over-the-counter distribution in
Australia, and possibly, other markets globally
** Adds that during period of exclusivity, GSK Consumer
Healthcare to undertake evaluation of commercial potential and
will review results of co's Phase 3 CBD clinical trial
** Stock down 3.5% this year, as of last close
(Reporting by Archishma Iyer)
((Archishma.Iyer@thomsonreuters.com;))